Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

The role of AIB1 and PAX2 in primary breast cancer: validation of AIB1 as a negative prognostic factor.

Alkner, Sara LU ; Bendahl, Po ; Grabau, Dorthe LU ; Malmström, Per LU ; Fernö, Mårten LU and Rydén, Lisa LU orcid (2013) In Annals of Oncology 24(5). p.1244-1252
Abstract
BackgroundThe steroid-receptor coactivator amplified in breast cancer one (AIB1) is implicated to be a prognostic factor, although the results are not unanimous. Recently its effect was suggested to be modified by paired box 2 gene product (PAX2).Patients and methodsUsing immunohistochemistry (IHC) AIB1 and PAX2 were investigated in two cohorts of early breast cancer, including systemically untreated premenopausal lymph-node-negative women and pre- and postmenopausal women receiving tamoxifen.ResultsAIB1 scores were available for 490 patients and PAX2 scores were available for 463 patients. High AIB1 was a negative prognostic factor for distant disease-free survival (DDFS, P = 0.02) and overall survival (OS, P < 0.001) in systemically... (More)
BackgroundThe steroid-receptor coactivator amplified in breast cancer one (AIB1) is implicated to be a prognostic factor, although the results are not unanimous. Recently its effect was suggested to be modified by paired box 2 gene product (PAX2).Patients and methodsUsing immunohistochemistry (IHC) AIB1 and PAX2 were investigated in two cohorts of early breast cancer, including systemically untreated premenopausal lymph-node-negative women and pre- and postmenopausal women receiving tamoxifen.ResultsAIB1 scores were available for 490 patients and PAX2 scores were available for 463 patients. High AIB1 was a negative prognostic factor for distant disease-free survival (DDFS, P = 0.02) and overall survival (OS, P < 0.001) in systemically untreated women, while no prognostic effect was seen in the tamoxifen-treated cohort, indicating AIB1 to be a predictor of tamoxifen response. In systemically untreated patients, PAX2 was not a prognostic factor, nor did it modify the effect of AIB1. However, in ER-positive patients receiving tamoxifen, PAX2 appeared to be a positive prognostic factor in premenopausal patients, while a negative factor in postmenopausal. The interaction between the menopausal status and PAX2 was significant (P = 0.01).ConclusionsIn an independent cohort of low-risk premenopausal patients, we validate AIB1 as a negative prognostic factor, indicating AIB1 to be an interesting target for new anti-cancer therapies. The effect of PAX2 warrants further studies. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Annals of Oncology
volume
24
issue
5
pages
1244 - 1252
publisher
Oxford University Press
external identifiers
  • wos:000318105000014
  • pmid:23230135
  • scopus:84877130463
  • pmid:23230135
ISSN
1569-8041
DOI
10.1093/annonc/mds613
language
English
LU publication?
yes
id
2d65ed78-dd11-4d15-8e42-756ef980c1e1 (old id 3347307)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/23230135?dopt=Abstract
date added to LUP
2016-04-01 10:34:01
date last changed
2022-03-19 21:55:34
@article{2d65ed78-dd11-4d15-8e42-756ef980c1e1,
  abstract     = {{BackgroundThe steroid-receptor coactivator amplified in breast cancer one (AIB1) is implicated to be a prognostic factor, although the results are not unanimous. Recently its effect was suggested to be modified by paired box 2 gene product (PAX2).Patients and methodsUsing immunohistochemistry (IHC) AIB1 and PAX2 were investigated in two cohorts of early breast cancer, including systemically untreated premenopausal lymph-node-negative women and pre- and postmenopausal women receiving tamoxifen.ResultsAIB1 scores were available for 490 patients and PAX2 scores were available for 463 patients. High AIB1 was a negative prognostic factor for distant disease-free survival (DDFS, P = 0.02) and overall survival (OS, P &lt; 0.001) in systemically untreated women, while no prognostic effect was seen in the tamoxifen-treated cohort, indicating AIB1 to be a predictor of tamoxifen response. In systemically untreated patients, PAX2 was not a prognostic factor, nor did it modify the effect of AIB1. However, in ER-positive patients receiving tamoxifen, PAX2 appeared to be a positive prognostic factor in premenopausal patients, while a negative factor in postmenopausal. The interaction between the menopausal status and PAX2 was significant (P = 0.01).ConclusionsIn an independent cohort of low-risk premenopausal patients, we validate AIB1 as a negative prognostic factor, indicating AIB1 to be an interesting target for new anti-cancer therapies. The effect of PAX2 warrants further studies.}},
  author       = {{Alkner, Sara and Bendahl, Po and Grabau, Dorthe and Malmström, Per and Fernö, Mårten and Rydén, Lisa}},
  issn         = {{1569-8041}},
  language     = {{eng}},
  number       = {{5}},
  pages        = {{1244--1252}},
  publisher    = {{Oxford University Press}},
  series       = {{Annals of Oncology}},
  title        = {{The role of AIB1 and PAX2 in primary breast cancer: validation of AIB1 as a negative prognostic factor.}},
  url          = {{http://dx.doi.org/10.1093/annonc/mds613}},
  doi          = {{10.1093/annonc/mds613}},
  volume       = {{24}},
  year         = {{2013}},
}